BioPorto (BIOPOR.CO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Denmark · ISIN DK0011048619

Price
1.03 DKK
Market cap
550.96 m DKK
P/E (2025)
–
P/S (2025)
13.68
Dividend yield
0.00 %
Net margin
-203.83 %
Return on equity (ROE)
-130.33 %
Return on assets (ROA)
-88.13 %

BioPorto financials

Fiscal year20242025
Revenue36.24 m DKK40.29 m DKK
Gross profit24.53 m DKK28.01 m DKK
Operating income-75.45 m DKK-86.09 m DKK
EBIT-72.91 m DKK-87.07 m DKK
Net income-68.24 m DKK-82.12 m DKK
Diluted EPS – continuing operations-0.17 DKK-0.15 DKK

Full history since 1999, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.